Current Report Filing (8-k)
May 14 2018 - 1:54PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2018
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14888
|
|
33-0969592
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
(Address of principal executive offices, including zip code)
(267)
440-4200
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07
.
|
Submission of Matters to a Vote of Security Holders
.
|
On May 11, 2018, Inovio
Pharmaceuticals, Inc. (the Company) held its 2018 Annual Meeting of Stockholders (the Annual Meeting). At the Companys Annual Meeting, the stockholders considered three proposals, each of which is described in more
detail in the Companys definitive proxy statement filed with the Securities and Exchange Commission on March 28, 2018. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal 1
: The election of the following nominees as directors of the Company to serve until the Companys 2019 Annual Meeting of Stockholders
and until their successors are elected. The votes were cast as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Name of Director Nominee
|
|
Votes For
|
|
|
Votes
Withheld
|
|
|
Broker
Non-Votes
|
|
Avtar S. Dhillon
|
|
|
19,863,245
|
|
|
|
8,359,633
|
|
|
|
44,348,217
|
|
J. Joseph Kim
|
|
|
27,410,990
|
|
|
|
811,888
|
|
|
|
44,348,217
|
|
Simon X. Benito
|
|
|
26,677,359
|
|
|
|
1,545,519
|
|
|
|
44,348,217
|
|
Ángel Cabrera
|
|
|
26,801,438
|
|
|
|
1,421,440
|
|
|
|
44,348,217
|
|
Morton Collins
|
|
|
27,559,741
|
|
|
|
663,137
|
|
|
|
44,348,217
|
|
Adel A.F. Mahmoud
|
|
|
27,128,627
|
|
|
|
1,094,251
|
|
|
|
44,348,217
|
|
David B. Weiner
|
|
|
27,533,921
|
|
|
|
688,957
|
|
|
|
44,348,217
|
|
Wendy Yarno
|
|
|
26,670,083
|
|
|
|
1,552,795
|
|
|
|
44,348,217
|
|
Proposal 2
: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst &
Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. The votes were cast as follows:
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
67,520,612
|
|
3,605,110
|
|
1,445,373
|
|
0
|
Proposal 3
: The approval, on a
non-binding
advisory basis, of the compensation
of the Companys named executive officers described in the Companys definitive proxy statement with respect to the Annual Meeting. The votes were cast as follows:
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
25,973,640
|
|
1,841,598
|
|
407,640
|
|
44,348,217
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INOVIO PHARMACEUTICALS, INC.
|
|
|
|
|
Date: May 14, 2018
|
|
|
|
By:
|
|
/s/ Peter Kies
|
|
|
|
|
|
|
Peter Kies
|
|
|
|
|
|
|
Chief Financial Officer
|
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024